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Abstract
Background: A recent genome wide case-control association study identified NuMA region on
11q13 as a candidate locus for breast cancer susceptibility. Specifically, the variant Ala794Gly was
suggested to be associated with increased risk of breast cancer.
Methods: In order to evaluate the NuMa gene for breast cancer susceptibility, we have here
screened the entire coding region and exon-intron boundaries of NuMa in 92 familial breast cancer
patients and constructed haplotypes of the identified variants. Five missense variants were further
screened in 341 breast cancer cases with a positive family history and 368 controls. We examined
the frequency of Ala794Gly in an extensive series of familial (n = 910) and unselected (n = 884)
breast cancer cases and controls (n = 906), with a high power to detect the suggested breast cancer
risk. We also tested if the variant is associated with histopathologic features of breast tumors.
Results: Screening of NuMA resulted in identification of 11 exonic variants and 12 variants in
introns or untranslated regions. Five missense variants that were further screened in breast cancer
cases with a positive family history and controls, were each carried on a unique haplotype. None
of the variants, or the haplotypes represented by them, was associated with breast cancer risk
although due to low power in this analysis, very low risk alleles may go unrecognized. The NuMA
Ala794Gly showed no difference in frequency in the unselected breast cancer case series or familial
case series compared to control cases. Furthermore, Ala794Gly did not show any significant
association with histopathologic characteristics of the tumors, though Ala794Gly was slightly more
frequent among unselected cases with lymph node involvement.
Conclusion: Our results do not support the role of NuMA variants as breast cancer susceptibility
alleles.
Background
Recently, a genome-wide association study with over 25
000 single-nucleotide polymorphisms (SNP) was con-
ducted to discover variants associated with increased
breast cancer risk [1]. The initial sample set comprised of
254 German breast cancer cases and 268 controls [1].
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Fifty-two SNPs were selected for replication genotyping in
two independent sample series, one German (188 cases,
150 controls) and one Australian (180 cases, 180 con-
trols) and, among others; a putative breast cancer suscep-
tibility locus was identified at 11q13. The variant with
strongest association in the 300 kb region was SNP
(rs673478) in an intron of gene LOC220074, p = 0.011
and OR = 1.59 (for combined discovery and replication
sets). The high-linkage disequilibrium 300 kb-block was
fine-mapped using an additional set of SNPs. The block
contains seven annotated genes of which the NuMA gene
spanning ~75 kb in the center of the block was chosen as
a candidate for breast cancer association. Four SNPs from
the fine-mapping SNP set in NuMA were carefully chosen
and genotyped in all three sample sets. The strongest asso-
ciation with breast cancer was observed for SNP
rs3750913 located in exon 16, which leads to an amino
acid substitution Ala794Gly in NuMA protein (p = 0.002,
OR = 2.13, for combined sample sets). Furthermore, Kam-
merer at al. reported an even stronger association for
Ala794Gly with familial breast cancer: comparison of fre-
quency in cases with family history of cancer with controls
is reported to result in p-value of 0.001 and OR = 4.45 [1].
NuMA  (Nuclear  Mitotic  Apparatus protein) gene is
located on chromosome 11q13 and it encodes a 236 kDa
nuclear protein essential for normal mitotic spindle
organization. NuMA protein consists of globular head
and tail domains and a separating long coiled-coil
domain [2] which mediates dimerization and oligomeri-
zation of NuMA [3]. The tail domain itself is bipartite
including a region critical for interaction with the mitotic
spindle and another region needed for accurate nuclear
reformation including a nuclear localization signal [4-6].
Expression of NuMA with deletion in either head or tail
domains results in dominant defects in mitosis [7].
NuMA  has been associated with acute promyelocytic
leukemia (APL). In very rare cases of APL translocation
NuMA-RARα (retinoic acid receptor α)
t(11;17)(q13;q21) has been observed instead of the com-
mon translocation involving a gene fusion of promyelo-
cytic leukemia protein (PML) and RARα [8]. The fusion
protein consists of 1883 amino acids of NuMA protein in
the aminoterminal end the rest of the total 2285 amino
acid protein being derived from RARα – the structure sim-
ilar to all RARα fusion proteins seen in APL. The essential
feature of the fusion partner NuMA is to be capable of
establishing protein-protein interactions that may result
in formation of defective heterodimers interfering with
retinoid signaling [8]. It has been reported that NuMA is
an interaction partner of GAS41 (glioma-amplified
sequence 41) [9], which is a highly conserved protein and
a putative transcription factor amplified in even at early
stages of human glioma [10]. This interaction links the
structural protein NuMA to the regulation of gene expres-
sion. In addition to the previously mentioned studies the
role of NuMA has not been under extensive research in
association with cancer.
In this study, we screened the NuMA gene for genetic var-
iants in breast cancer cases and studied their relevance for
breast cancer risk. In particular, we studied the association
of the reported breast cancer susceptibility allele NuMA
Ala794Gly in larger series of unselected and familial
breast cancer cases and controls, and examined the associ-
ation of this variant with clinicopathologic characteristics
of breast tumors.
Methods
Breast cancer patients
The 28 exons and exon-intron boundaries as well as 5' and
3' untranslated regions (ENST00000358965) were
screened for sequence variants in a total of 92 familial
(non-BRCA1/2) breast cancer cases. Familial breast cancer
case was here, in this initial screening, defined as three or
more breast cancer cases in first degree family members
(including the index case).
A number of identified variants were selected, based on
bioinformatic analyses, for further exploratory screening
in familial breast cancer patients (n = 341) and healthy
population controls (n = 368). The previously identified
possible risk variant Ala794Gly was screened in larger
series of familial (n = 910) and unselected breast cancer
cases (n = 884), and compared in frequency with popula-
tion controls (n = 906). The unselected breast cancer case
series included consecutive newly diagnosed breast cancer
patient samples collected at the Department of Oncology,
Helsinki University Central Hospital at two separate peri-
ods in 1997–1998 and 2000 covering 79% of all newly
diagnosed breast cancer cases at respective study periods
combined (for more detailed description, see [11,12]. The
series of familial breast cancer cases in this study have
been collected at the Helsinki University Central Hospital
as described in [13]. The successfully genotyped series
included 378 patients with strong family history, defined
as three or more breast or ovarian cancer cases in the first
or second degree family members including the index
case. The latter series were screened negative for BRCA1/2
mutations (previously described in detail in [14-16]. The
remaining 515 successfully genotyped familial cases had a
single affected first degree family member; for 312 of these
cases, the Finnish BRCA1/2 founder mutations have been
excluded as described [14,15]. The cancer diagnoses have
been verified through the Finnish Cancer Registry and
hospital records.
Histopathologic data were collected from pathology
reports for all the primary breast tumors available fromBMC Cancer 2008, 8:71 http://www.biomedcentral.com/1471-2407/8/71
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the unselected case series (889 tumors from 842 success-
fully genotyped cases). The data set in this study includes
information on tumor histology, grade, estrogen and pro-
gesterone receptor status, p53 immunohistochemistry,
tumor diameter, lymph node status, distant metastases,
and the age at the time of diagnosis.
The study was performed with informed consent from the
patients and permissions from the Ethics Committee of
the Department Obstetrics and Gynecology, as well as
from the Ministry of Social Affairs and Health in Finland.
Variant screening
All NuMA exons were screened for sequence variants
using single strand conformation polymorphism (SSCP)
or conformation sensitive gel electrophoresis (CSGE)
method. For further screenings restriction fragment poly-
morphism (RFLP) method was used when applicable.
Variant Arg972Gln (R972Q) was screened by RFLP using
enzyme BsrBI, Arg1471Trp (R1471W) using enzyme
MspI), and Arg1665Cys (R1665C) using enzyme HhaI.
For the screening of intronic variant IVS2+34G > C a
mutagenesis primer was designed to create a restriction
site for enzyme NdeI. Primer sequences are available on
request. All endonucleases are products of New England
BioLabs, Beverly, MA. All variants found in the screening
have been confirmed by either DNA sequencing or repeat-
ing the screening by respective method (SSCP, CSGE,
RFLP) for the genomic DNA sample. The genotyping
Ala794Gly has been performed using Amplifluor™ fluo-
rescent genotyping (K-Biosciences, Cambridge, UK). The
quality of the Ala794Gly genotyping was ascertained by
analyzing duplicate samples (92 samples were genotyped
with 100% concordance). Genotyping success rate for
unselected cases was 95% (842/884), for familial cases
98% (893/910), and 100% for population controls (906/
906)]. The unsuccesfull genotypes were due to poor qual-
ity or lack of DNA in the analysis.
Statistical and Bioinformatic Methods
Standard chi squared or Fisher exact tests were used to
assess the differences in genotype frequencies between
groups. Per allele odds ratios for each SNP, together with
95% confidence intervals, were estimated using logistic
regression. Differences in survival by genotype were
assessed using the log-rank test. Analyses were performed
using SPSS (SPSS Inc., Chicago, IL). All p-values are two-
sided. SIFT [17,18] and PolyPhen [19,20] were used for
predicting the impact of observed amino acid substitu-
tions on the structure and function of NuMA protein. The
most probable haplotypes were reconstructed using the
program PHASE [21-23].
Results
A total of 11 exonic and 12 intronic or untranslated region
(UTR) variants in NuMA were identified (Table 1). We
selected 5 of these variants, in addition to Ala794Gly, for
further analysis. These five variants had a SIFT score lower
than or similar to the score for Ala794Gly (SIFT score
0.29). In particular, two variants (Arg218Trp and
Table 1: Variants identified in NuMA and their predicted effect on protein level by SIFT and PolyPhen
Location Variant Frequency SIFT PolyPhen
IVS2 IVS2+34 G > C 4/92
IVS4 IVS4+46 delCA 19/92
IVS5 IVS5+23 T > A 3/92
IVS5 IVS5-18 G > A 19/92
IVS6 IVS6-53 A > G 19/92
IVS8 IVS8-52 T > A 19/92
ex 10 652 C > T, Arg218Trp 1/92 0.00 unknown
IVS12 IVS12-37 insA 19/92
IVS14 IVS14+32 G > T 9/92
ex 15 2381 C > G, Ala794Gly 9/92 0.29 benign
ex 15 2484C > T, Gly828Gly 1/92 -
ex 15 2915 G > A, Arg972Gln 3/92 0.30 benign
ex 15 4012 G > A, Glu1338Lys 1/92 0.28 benign
ex 15 4411 C > T, Arg1471Trp 2/92 0.00 possibly damaging
ex 17 4785 G > A, Lys1595Lys 1/92 -
ex 18 4996 C > T, Arg1665Cys 1/92 0.03 possibly damaging
IVS18 IVS18+15 C > G 1/92
ex 20 5335 G > A, Asp1779Asn 3/92 1.00 benign
ex 21 5619 C > T, Ala1873Ala 9/92 -
ex 25 6083 G > A, Arg2028Gln 1/92 0.94 benign
3' UTR 6517 A > C 10/92
3' UTR 6519 C > G 10/92
3' UTR 6580 T > C 1/92BMC Cancer 2008, 8:71 http://www.biomedcentral.com/1471-2407/8/71
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Arg1471Trp) had a SIFT score was 0.00, which may indi-
cate that the amino acid substitution is harmful to the
protein. We genotyped these variants in 341 familial
breast cancer patients and 368 population controls. All
were present at a similar frequency in cases and controls.
(Table 2).
The Ala794Gly variant was present in 5.8% of population
controls (53/906), 5.7% of unselected breast cancer cases
(48/842) and 4.8% of familial breast cancer cases (43/
893) (Table 3). Thus there was no evidence for an associ-
ation between Ala794Gly genotype and breast cancer risk.
NuMA Ala794Gly did not show any significant associa-
tion with histopathologic parameters of the tumors (Table
4). There was some evidence of an association between
the Ala794Gly variant and positive lymph node status in
unselected breast cancer case series (p = 0.008), but this
association was not seen among familial patient series
(data not shown). Furthermore, if Bonferroni correction
for multiple testing was applied, only p-value of 0.006 or
smaller would be considered significant. There was no dif-
ference in either overall or disease-free survival by
Ala794Gly genotype (data not shown).
Observed variants in NuMA were used for reconstructing
haplotypes using PHASE program (Table 5). Altogether
15 different haplotypes defined by 23 sequence variants
in NuMA were observed in the screening of 92 familial
breast cancer patients (Table 5). The most common hap-
lotype (without any observed DNA sequence variants)
accounts for 80% of observed haplotypes, and together
the three most common haplotypes account for 90% of
haplotypes. Each of the missense variants that were fur-
ther studied represent a unique haplotype except the
Ala794Gly which is present in two haplotypes (numbers
12 and 14 in Table 5) defined by an intronic variant
IVS2+34 G > C. In order to study the possibility that either
of haplotypes 12 or 14 would associate with breast cancer
risk we screened the haplotype-defining intronic variant
IVS2+34G > C in 337 familial breast cancer cases and 359
controls. Variant IVS2+34G > C was present in cases and
controls in similar proportions (cases 49/337, 14.5% and
controls 57/359, 16.0%; p = 0.6). Furthermore, we did not
observe any haplotype 12 carriers in this further screening
(variant IVS2+34G > C was always present in Ala794Gly
carriers).
Discussion
Kammerer et al. utilized a genome-wide association anal-
ysis to identify breast cancer susceptibility regions and
identified, among other regions, a high-linkage disequi-
librium region on chromosome 11q13 [1]. This region
contains several genes and NuMA was chosen as a most
Table 3: Results from NuMA A794G screening
total C:C C:G p2 OR2 95%CI
Population controls 906 853(94.2%) 53(5.8%)
Unselected cases 842 794(94.3%) 48(5.7%) 0.89 0.97 0.65–1.45
bilateral breast cancer 54 50(92.6%) 4(7.4%) 0.5413 1.35 0.47–3.92
unilateral breast cancer 788 744(94.4%) 44(5.6%)
multiple cancers1 84 81(96.4%) 3(3.6%) 0.6173 0.59 0.18–1.93
no multiple cancers 758 713(94.1%) 45(5.9%)
Familial cases 893 850(95.2%) 43(4.8%) 0.33 0.81 0.54–1.23
3+ families 378 359(95.0%) 19(5.0%) 0.56 0.85 0.50–1.46
breast cancer only 298 283(95.0%) 15(5.0%)
breast and ovarian cancer 80 76(95.0%) 4(5.0%)
Small families 515 491(95.3%) 24(4.7%) 0.34 0.79 0.48–1.29
1case with at least one other cancer than breast cancer
2compared to population controls, except comparisons between unilateral vs. bilateral and multiple cancers vs. one cancer
3Fisher's exact test
No G:G genotypes were observed.
Table 2: Further screening of selected variants in familial breast cancer cases and controls.
Exon Variant Familial Cases Controls
10 ex10 652 C > T, Arg218Trp 1/341 1/368
15 ex15 2915 G > A, Arg972Gln 6/333 12/364
15 ex15 4012 G > A, Glu1338Lys 1/323 1/364
15 ex15 4411 C > T, Arg1471Trp 2/339 0/368
18 ex 18 4996 C > T, Arg1665Cys 7/337 6/366BMC Cancer 2008, 8:71 http://www.biomedcentral.com/1471-2407/8/71
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likely candidate for breast cancer susceptibility gene, and
variant Ala794Gly was hypothesized to be functionally
impaired and suggested to be associated with breast can-
cer risk [1].
Our thorough screening of NuMA gene in breast cancer
cases resulted in identification of several variants of which
eight were missense changes and the rest were synony-
mous variants or not located in coding regions. Missense
variants that warranted further screening after bioinfor-
matic analyses were present in the breast cancer cases in
similar frequencies as in controls. Variant Arg1471Trp was
not detected in controls, however, but being present in
only 0.6% of the cases would have only marginal effect on
breast cancer even if having any effect on breast cancer risk
for the carriers. These variants represented also unique
haplotypes, not suggesting presence of other risk alleles in
linkage disequilibrium with these variants either,
although due to low power, very low risk alleles may go
unrecognized.
We also specifically evaluated the variant NuMA
Ala794Gly for breast cancer risk in an extensive patient
series (884 unselected cases, 910 familial cases and 906
population controls) as compared to those used by Kam-
merer et al, (2005) [1]. For this analysis, our material has
98% power to detect a difference in frequency of that mag-
nitude.
Variant Ala794Gly was detected in almost equal frequen-
cies in all our study series as well as in population con-
trols, which is consistent with the results from a large
Table 4: Tumor characteristics among 842 unselected breast cancer cases analyzed for NuMA A794G.
NuMA A794G (2381C > G) p
Total CC CG
Total n = 889 837(94.2%) 52(5.8%)
Histology n = 889 ND
Ductal 599(71.6%) 39(75.0%)
Lobular 132(15.8%) 8(15.4%)
Medullary 11(1.3%) 1(1.9%)
other 95(11.4%) 4(7.7%)
Gradus n = 793 0.107
1 208(27.9%) 7(14.9%)
2 316(42.4%) 26(55.3%)
3 222(29.8%) 14(29.8%)
pT Stage n = 801 0.767 (Fisher)
pT1-pT2 699(92.6%) 44(95.7%)
pT3-pT4 56(7.4%) 2(4.3%)
Lymph Nodes n = 858 0.008
pN0 446(55.3%) 360(44.7%)
pN1-2 19(36.5%) 33(63.4%)
Estrogen Receptor Status n = 845 0.691
Positive 622(78.4%) 42(80.8%)
Negative 171(21.6%) 10(19.2%)
Progesterone Receptor Status n = 846 0.425
Positive 538(67.8%) 38(73.1%)
Negative 256(32.2%) 14(26.9%)
p53 Status n = 653 0.035
Positive 132(21.3%) 2(6.1%)
Negative 488(78.7%) 31(93.9%)
Distant metastasis n = 853 0.161 (Fisher)
Positive 41(5.1%) 0(0.0%)
Negative 765(94.9%) 47(100.%)
The mean age of diagnosis was 57 years for C:C, and 56 for C:G genotypes.BMC Cancer 2008, 8:71 http://www.biomedcentral.com/1471-2407/8/71
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breast cancer patient and control series recently studied by
the Breast Cancer Association Consortium [24] and does
not support the previously proposed association with
breast cancer risk. However, as the variant Ala794Gly was
initially found here to be present in two distinct haplo-
types defined by an intronic variant it is possible that dif-
ferences in the relative haplotype frequencies could have
masked any associated risk. Further evaluation of these
two haplotypes, however, did not support this possibility.
None of the identified NuMA variants was associated with
breast cancer risk in our study. Furthermore, Ala794Gly
variant was not significantly associated with any of the
tumor characteristics.
Conclusion
In conclusion, our results do not support the role of
NuMA variants as breast cancer risk alleles.
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